FHTX

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Foghorn Therapeutics Inc

NASDAQ | FHTX

4.26

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 13, 2025)

$229.51M

Market Cap

-

P/E Ratio

-1.14

EPS

$9.69

52 Week High

$2.94

52 Week Low

HEALTHCARE

Sector

FHTX Chart

Recent Chart
Price Action

FHTX Technicals

Tags:

FHTX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $23M
Total Revenue $23M
Cost Of Revenue $3.1M
Costof Goods And Services Sold $3.1M
Operating Income -$103M
Selling General And Administrative $28M
Research And Development $95M
Operating Expenses $125M
Investment Income Net -
Net Interest Income $12M
Interest Income $12M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $3.1M
Income Before Tax -$87M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$87M
Comprehensive Income Net Of Tax -
Ebit -$100M
Ebitda -$97M
Net Income -$87M

Revenue & Profitability

Earnings Performance

FHTX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $284M
Total Current Assets $250M
Cash And Cash Equivalents At Carrying Value $55M
Cash And Short Term Investments $55M
Inventory -
Current Net Receivables -
Total Non Current Assets $34M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $188M
Other Current Assets $5.9M
Other Non Current Assets -
Total Liabilities $330M
Total Current Liabilities $67M
Current Accounts Payable $3.8M
Deferred Revenue -
Current Debt -
Short Term Debt $18M
Total Non Current Liabilities $263M
Capital Lease Obligations $37M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $37M
Other Current Liabilities -$536K
Other Non Current Liabilities -
Total Shareholder Equity -$46M
Treasury Stock -
Retained Earnings -$558M
Common Stock $6K
Common Stock Shares Outstanding $55M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$100M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $3.1M
Capital Expenditures $906K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$30M
Cashflow From Financing $105M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$87M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $23M
Total Revenue $23M
Cost Of Revenue $3.1M
Costof Goods And Services Sold $3.1M
Operating Income -$103M
Selling General And Administrative $28M
Research And Development $95M
Operating Expenses $125M
Investment Income Net -
Net Interest Income $12M
Interest Income $12M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $3.1M
Income Before Tax -$87M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$87M
Comprehensive Income Net Of Tax -
Ebit -$100M
Ebitda -$97M
Net Income -$87M

FHTX News

FHTX Profile

Foghorn Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapeutics that target genetic dependencies in the chromatin regulatory system. Leveraging its proprietary Gene Traffic Control platform, Foghorn aims to uncover novel treatments for various cancers and genetic disorders, positioning itself at the forefront of precision medicine. With a robust pipeline of candidates in clinical trials, Foghorn is dedicated to advancing its mission of transforming patient outcomes through targeted therapies.

VHAI
-25.00%
$0.00
YYAI
-12.21%
$0.16
STAI
+39.44%
$0.62
CGBS
-39.47%
$0.03
BURU
+6.25%
$0.50
ELBM
+334.95%
$7.17
PLUG
+13.44%
$3.87
GWH
+149.66%
$10.38
RGTI
+20.26%
$52.82
ASST
-35.33%
$1.00
BITF
+25.47%
$5.26
IONZ
-35.04%
$2.21
BYND
-47.01%
$1.06
NVDA
+2.25%
$187.29
NVTS
+23.51%
$10.16
DNN
+6.94%
$3.07
CAN
+33.93%
$1.45
QBTS
+23.97%
$40.93
INTC
+2.03%
$37.11
GPUS
-12.50%
$0.41
WULF
-0.58%
$13.51
JOBY
+2.61%
$16.70
AXDX
-61.36%
$0.03
BBD
+1.30%
$3.10
TSLA
+5.01%
$434.23
CLF
+5.50%
$13.90
F
+0.96%
$11.52
QS
+16.36%
$17.10
CRML
+56.07%
$23.38
NIO
+6.59%
$7.15
ETHD
-11.62%
$3.37
AMD
+0.40%
$215.76
PWM
+12.50%
$1.17
RXRX
+4.41%
$5.55
CIFR
+19.77%
$20.32
LAES
+13.49%
$6.14
APLD
+2.14%
$34.71
BTBT
+5.58%
$3.97
SOFI
+4.45%
$27.35
DVLT
-12.36%
$1.66
TLRY
+0.58%
$1.73
DFLI
+41.35%
$1.54
ONDS
+18.43%
$10.92
RR
+7.85%
$6.38
ACHR
+6.64%
$12.76
SOUN
+10.77%
$19.23
WBD
-3.22%
$17.10
MP
+23.30%
$96.60
NAK
+26.47%
$2.56
USAR
+22.60%
$39.97
RMBL
+60.50%
$3.21
IREN
+8.04%
$64.58
ABAT
+34.34%
$9.06
ADD
-25.47%
$0.05
CORZ
+2.66%
$18.52
UUUU
+18.40%
$24.08
AAL
+1.51%
$11.69
RIG
+3.24%
$3.18
MARA
+9.43%
$20.40
EPWK
-11.00%
$0.08
NAKA
-4.05%
$0.83
UAMY
+37.67%
$16.80
PLTR
+0.84%
$176.92
SRM
+53.27%
$10.30
NOK
-1.79%
$5.22
IONQ
+18.72%
$83.88
PFE
+0.10%
$24.80
ADAP
-0.70%
$0.18
BMNR
+7.40%
$56.35
QUBT
+10.49%
$21.01
GDXD
-12.99%
$0.74
SNAP
+3.14%
$8.02
XCH
+119.76%
$1.81
CJET
-14.93%
$0.12
MRVL
-5.52%
$85.61
BULL
+1.62%
$11.58
NB
+3.81%
$10.78
CLSK
+2.49%
$19.76
BINI
-55.00%
$0.63
MULN
-55.00%
$0.63
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
AMZN
+1.81%
$220.30
AVGO
-5.90%
$324.63
NEHC
-8.12%
$2.60
WLGS
-5.57%
$0.04
BTG
+3.87%
$5.27
KDLY
-7.21%
$0.87
AMC
+0.68%
$2.95
ETWO
0.00%
$3.30
RF
+1.84%
$24.60
QSI
+23.35%
$2.06
HPE
+2.76%
$25.07
PMAX
+75.28%
$4.54
TMC
+18.40%
$10.52
ABEV
+1.42%
$2.14
KDP
+3.02%
$26.60
RGTZ
-42.68%
$10.66
T
-1.10%
$25.58
SMR
+15.95%
$45.50
VHAI
-25.00%
$0.00
YYAI
-12.21%
$0.16
STAI
+39.44%
$0.62
CGBS
-39.47%
$0.03
BURU
+6.25%
$0.50
ELBM
+334.95%
$7.17
PLUG
+13.44%
$3.87
GWH
+149.66%
$10.38
RGTI
+20.26%
$52.82
ASST
-35.33%
$1.00
BITF
+25.47%
$5.26
IONZ
-35.04%
$2.21
BYND
-47.01%
$1.06
NVDA
+2.25%
$187.29
NVTS
+23.51%
$10.16
DNN
+6.94%
$3.07
CAN
+33.93%
$1.45
QBTS
+23.97%
$40.93
INTC
+2.03%
$37.11
GPUS
-12.50%
$0.41
WULF
-0.58%
$13.51
JOBY
+2.61%
$16.70
AXDX
-61.36%
$0.03
BBD
+1.30%
$3.10
TSLA
+5.01%
$434.23
CLF
+5.50%
$13.90
F
+0.96%
$11.52
QS
+16.36%
$17.10
CRML
+56.07%
$23.38
NIO
+6.59%
$7.15
ETHD
-11.62%
$3.37
AMD
+0.40%
$215.76
PWM
+12.50%
$1.17
RXRX
+4.41%
$5.55
CIFR
+19.77%
$20.32
LAES
+13.49%
$6.14
APLD
+2.14%
$34.71
BTBT
+5.58%
$3.97
SOFI
+4.45%
$27.35
DVLT
-12.36%
$1.66
TLRY
+0.58%
$1.73
DFLI
+41.35%
$1.54
ONDS
+18.43%
$10.92
RR
+7.85%
$6.38
ACHR
+6.64%
$12.76
SOUN
+10.77%
$19.23
WBD
-3.22%
$17.10
MP
+23.30%
$96.60
NAK
+26.47%
$2.56
USAR
+22.60%
$39.97
RMBL
+60.50%
$3.21
IREN
+8.04%
$64.58
ABAT
+34.34%
$9.06
ADD
-25.47%
$0.05
CORZ
+2.66%
$18.52
UUUU
+18.40%
$24.08
AAL
+1.51%
$11.69
RIG
+3.24%
$3.18
MARA
+9.43%
$20.40
EPWK
-11.00%
$0.08
NAKA
-4.05%
$0.83
UAMY
+37.67%
$16.80
PLTR
+0.84%
$176.92
SRM
+53.27%
$10.30
NOK
-1.79%
$5.22
IONQ
+18.72%
$83.88
PFE
+0.10%
$24.80
ADAP
-0.70%
$0.18
BMNR
+7.40%
$56.35
QUBT
+10.49%
$21.01
GDXD
-12.99%
$0.74
SNAP
+3.14%
$8.02
XCH
+119.76%
$1.81
CJET
-14.93%
$0.12
MRVL
-5.52%
$85.61
BULL
+1.62%
$11.58
NB
+3.81%
$10.78
CLSK
+2.49%
$19.76
BINI
-55.00%
$0.63
MULN
-55.00%
$0.63
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
AMZN
+1.81%
$220.30
AVGO
-5.90%
$324.63
NEHC
-8.12%
$2.60
WLGS
-5.57%
$0.04
BTG
+3.87%
$5.27
KDLY
-7.21%
$0.87
AMC
+0.68%
$2.95
ETWO
0.00%
$3.30
RF
+1.84%
$24.60
QSI
+23.35%
$2.06
HPE
+2.76%
$25.07
PMAX
+75.28%
$4.54
TMC
+18.40%
$10.52
ABEV
+1.42%
$2.14
KDP
+3.02%
$26.60
RGTZ
-42.68%
$10.66
T
-1.10%
$25.58
SMR
+15.95%
$45.50
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.